HRA Pharma boosts presence in Europe with Italian Subsidiary

HRA Pharma, a privately-held France-based pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, says that it has established its Italian subsidiary, HRA Pharma Italia, thereby reinforcing its operational presence in Europe.

HRA Pharma Italia is the company's third subsidiary created since embarking on an aggressive growth plan targeting strengthened operations in key European countries, local management appointments and an expanded product portfolio.

Located in Rome, the news subsidiary will handle local marketing, sales and distribution of three HRA Pharma products: NorLevo, Lysodren and ellaOne. NorLevo, the first emergency contraception to be approved by health authorities, and Lysodren, for the symptomatic treatment of advanced adrenal cortical carcinoma, have been available in Italy since 2000 and 2004, respectively. ellaOne, a new generation emergency contraception, received its marketing authorization from the European Union in May 2009 and has not yet been launched. Alberto Aiuto, a pharmacist by training with over 30 years of industry experience within a number of pharmaceutical companies in Italy, has been named general manager of the subsidiary.